CVRs: The next big thing in biotech deals?
Yesterday we reported that Sanofi-Aventis and Genzyme continuing negotiations. But this financial representatives for both companies were hashing out the specifics of a contingent value right, or CVR, that would boost Sanofi's offer to $80 (from $69) if Genzyme's multiple sclerosis drug alemtuzumab is approved and/or hits certain sales milestones. Marketwatch takes a closer look at CVRs and speculates that they could become more popular in the world of biotech M&A as buyers seek to insulate themselves from risky acquisitions and sellers look to get the most money for their assets. Report